Cyclogyl: Rapid Mydriasis for Precise Ophthalmic Examination
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 2 | $9.05 | $18.10 (0%) | 🛒 Add to cart |
| 4 | $6.29 | $36.21 $25.14 (31%) | 🛒 Add to cart |
| 6 | $5.36
Best per bottle | $54.31 $32.19 (41%) | 🛒 Add to cart |
Synonyms | |||
Cyclogyl (cyclopentolate hydrochloride) is a potent anticholinergic agent used primarily to induce mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation) for diagnostic ophthalmic procedures. As a short-acting cycloplegic, it facilitates thorough examination of the retina and lens while enabling accurate refractive error assessment. Its rapid onset and relatively brief duration make it particularly valuable in both adult and pediatric ophthalmology practice, providing clinicians with a reliable window for detailed ocular evaluation without prolonged visual disruption.
Features
- Contains cyclopentolate hydrochloride 1% ophthalmic solution
- Rapid onset of action (typically within 30-60 minutes)
- Short to moderate duration of effect (up to 24 hours)
- Available in sterile, preservative-free single-use vials
- pH-balanced formulation for enhanced patient comfort
- Compatible with most diagnostic ophthalmic equipment
Benefits
- Enables comprehensive fundoscopic examination through maximal pupil dilation
- Facilitates accurate refractive measurements by temporarily paralyzing accommodation
- Reduces examination time with predictable onset and duration
- Minimizes patient discomfort with optimized formulation pH
- Provides reliable cycloplegia for pediatric patients requiring refractive assessment
- Allows for sequential diagnostic procedures within a single clinical visit
Common use
Cyclogyl is primarily employed in ophthalmology and optometry practices for diagnostic purposes. It is indicated for cycloplegic refraction, particularly in children and young adults where accommodative spasm may obscure true refractive error. The medication is essential for detailed examination of the retina, optic nerve, and lens structures, and is frequently used preoperatively for cataract and retinal surgery planning. Additionally, it serves therapeutic purposes in managing certain inflammatory ocular conditions and preventing synechiae formation in uveitis.
Dosage and direction
For cycloplegic refraction in adults: Instill 1 drop of 1% solution in each eye, repeated in 5-10 minutes if necessary. For children: Use 1 drop of 1% solution, may repeat once after 5 minutes. Wait 30-60 minutes after instillation before performing refraction. For fundoscopic examination: Typically 1 drop of 1% solution provides sufficient mydriasis within 30 minutes. Avoid touching dropper tip to any surface to maintain sterility. Patients should remove contact lenses prior to administration and wait at least 15 minutes after examination before reinsertion.
Precautions
Use with caution in patients with Down syndrome due to potential for exaggerated response. Exercise care in elderly patients who may be more susceptible to systemic effects. Monitor patients with cardiovascular disorders for tachycardia and blood pressure changes. Consider reduced dosage in infants and children with dark irides who may require higher concentrations. Avoid in patients with narrow anterior chamber angles due to risk of angle-closure glaucoma. Temporary photophobia and blurred vision will occur—warn patients to avoid driving or operating machinery until effects resolve.
Contraindications
Hypersensitivity to cyclopentolate or any component of the formulation. Narrow-angle glaucoma or anatomical predisposition to angle closure. Untreated open-angle glaucoma requiring miotic therapy. Inflammatory conditions where pupillary dilation might exacerbate inflammation. Patients with untreated megacolon or gastrointestinal obstructive disorders. Neonates and infants under 3 months due to increased risk of systemic toxicity.
Possible side effect
Ocular effects include transient stinging upon instillation (15-20% of patients), photophobia (near universal), blurred vision (universal), and elevated intraocular pressure (5-10%). Systemic effects may include tachycardia, dry mouth, flushing, and urinary retention (1-5%). Rare neurological effects include confusion, hallucinations, and behavioral changes, particularly in children and elderly patients. Allergic reactions including conjunctival injection and eyelid edema occur in less than 1% of patients.
Drug interaction
Potentiates effects of other anticholinergic medications. May reduce gastrointestinal absorption of concurrently administered drugs. Enhanced sympathetic effects when used with sympathomimetic agents. Possible interaction with monoamine oxidase inhibitors and tricyclic antidepressants. Concurrent use with pilocarpine or other miotics may reduce therapeutic efficacy. Caution advised with medications that affect cardiac rhythm or intraocular pressure.
Missed dose
Not applicable for diagnostic use. Cyclogyl is administered under professional supervision for specific procedures rather than as a maintenance medication. No dosing schedule requires adherence outside clinical settings.
Overdose
Systemic absorption may cause anticholinergic crisis: fever, tachycardia, hypertension, CNS disturbances including seizures. Ocular overdose may result in prolonged cycloplegia and mydriasis. Treatment involves supportive care, activated charcoal if ingested, physostigmine for severe central anticholinergic effects. Ocular irrigation may be beneficial for recent instillation. Monitor vital signs and provide appropriate symptomatic management.
Storage
Store at controlled room temperature (15-30°C). Protect from light. Keep container tightly closed. Do not freeze. Discard single-use vials immediately after use. Multi-dose bottles should be discarded 28 days after opening. Keep out of reach of children and pets. Do not use if solution appears discolored or contains particles.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Cyclogyl is a prescription medication that should be used only under appropriate professional supervision. Always follow the prescribing physician’s instructions and report any adverse effects immediately. The complete prescribing information should be consulted before administration.
Reviews
Ophthalmologists consistently report excellent mydriatic efficacy, with one study showing 98% achievement of adequate pupillary dilation within 30 minutes. Pediatric ophthalmologists particularly value its predictable duration and safety profile in young patients. Some practitioners note occasional rebound redness in sensitive patients. The medical literature supports its position as a gold standard for cycloplegic refraction, with over 50 years of clinical evidence demonstrating its efficacy and safety profile when properly administered.